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Abbreviations
Chemical substances and Drugs
BPA: Bisphenol-A
DAMGO: [D-Ala2,N-Me-Phe`,Gly5-ol]enkephalin
E2: 17P-Estradiol
E'GTA: Ethylene glycoi bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid
GDP: Guanosine-5'-diphosphate
GTPyS: Guanosine-5'-o-(3-thio)triphosphate
ICI182,780: 7q,17P-[9[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]-nonyl]estra-1,3,5(10)-
triene-3,17-diol
7--OH-DOAT: 7-Hydroxy-N,N--di-n-propyl -2-aminotetralin
SCH23390: (5R)-8-Chloro-3--methyl-5-phenyl-2,3,4,5-tetrahydro-IH-3-benzazepine-7-
ol
Buffers
BSS: Balanced salt saline
PBS: Phosphate-buffered saline
Brain regions
ac: Anterior commissure
CA: Cornu ammonis
i
DG: Dentate gyrus
N.Acc: Nucleus accumbens
VTA: Ventral tegmental area
Endogenous substances
ATP: Adenosine triphosphate
cAMP: Cyclic adenosine monophosphate
CREB: cAMP responsive element binding protein
FGF: Fibroblast growth factor
GABA: y-Aminobutyric acid
GAP-43: Growth associated protein-43
GAPDH: D-glyceraldehyde-3-phosphate dehydrogenase
GDNF: Glial cell-line derived neurotrophic factor
GFAP: Glial fibrillary acidic protein
LMX: LIM homeobox transcription factor
Pax: Paired- and homeodomain-containing transcription factor
Shh: Sonic hedgehog
TGF: Transforming growth factor
Rceptors and 1lransporters
D,R: Dopamine Di receptor
D,R: Dopamine D2 receptor
ii
D3R: Dopamine D3 receptor
DAT: Dopamine transporter
RXR: Retinoid receptor
Enzymes
ChAT: Choline acetyltransferase
TH: Tyrosine hydroxylase
Serum
FBS: Fetal bovin serum
NGS: Normal goat serum
HS: Normal horse serum
Injection routes
i.c.v.: Intracerebroventricular
p.o.: Per os
s.c.: Subcutaneous
Instruments
CPP: Conditioned place preference
RT--PCR: Reverse transcription-polymerase chain reaction
iii
Others
ANOVA: Analysis of variance
CNS: Central nervous system
DMEM: Dulbecco's modified Eagle's medium
EDs: Embryonic days
SPEED: Strategic Programs on Environmental Endocrine Disruptors
iv
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General Introduction
Endocrine disruptors
 The developing fetus utilizes natural hormonal messages and effects that originate in
its own hormone system and that of its mother for developmental guidance. These
hormonal messages influence virtually all characteristics of a developing fetus,
including those of its nervous system, sex, and reproductive system. "Our Stolen
Future" scientifically explores the adverse effects of endocrine disruptors on natural
hormones. Experiments on endocrine disruptors in laboratory animals have shown
conclusively that fetal exposure to environmental, synthesized, or natural
xenoestrogenic chemicals can wreak lifelong damage. Because comprehensive scientific
proof is lacking, much more evidence is necessary to justify further efforts in research,
public policy draft, and personal safety. A great many researches have indicated that
human exposure to endocrine disruptors can be prevented by various courses and routes.
Moreover, the chemical exposure levels in humans must be determined to grasp the
state of environmental pollution. Therefore an assessment of the extent of exposure to
endocrine disruptors is vital to promoting human health and preventive medicine.
 The report entitled "Global Assessment of the State-of-the-Science of Endocrine
Disruptors," published by the Intemational Programme on Chemical Safety, is a result
of a global comprehensive review of publicly available scientific literature on endocrine
disruptors. Furthermore, SPEED'981JEA's "Strategic Programs on Environmental
Endocrine Disruptors '98" from the Environmental Agency and health science research
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conducted by the Ministry of Health, Labour and Welfare, which deals with the risk
assessment of endocrine disruptors in Japan, have been published.
Bisphenol-A
 Bisphenol-A (4,4'-isopropylidene-2-diphenol) is one of the most common endocrine
disruptors. It is used as the monomer to manufacture polycarbonate plastic (the resin
that is used as linings for most food and beverage cans), as dental sealants, and as an
additive in other widely used consumer products. Bisphenol-A is one of the highest-
volume chemicals produced worldwide. Heat and contact with either acidic or basic
compounds accelerate hydrolysis of the ester bond linking bisphenol-A molecules in
polycarbonate and resins. Specifically, the heating of cans to sterilize food, the presence
of acidic or basic food or beverages in cans or polycarbonate plastic, and the repeated
washing of polycarbonate products have all been shown to result in an increase in the
rate of leaching of bisphenol-A'`).
 It has been reported that the administration of bisphenol-A to pregnant mice on
gestation days at a dose within the range typical of the environmental exposure of
humans produces significant changes in the postnatal growth rate and brings on early
puberty in these mice5). Thus bisphenol-A may cause toxicity in the developmental
process. Recent findings also demonstrated that chronic treatment with bisphenol-A
affects the development of the central nervous systems6). Furthermore, it has been
reported that prenatal and neonatal exposures to bisphenol-A markedly enhances the
pharmacological actions of drugs of abuse associated with the potentiation of the
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dopaminergic neurotransmission7L9).
Implications of the mesolimbic dopamine system in the rewarding effect
 Multiple lines of research have indicated the mesolimbic dopamine systems in drug
rewards, including psychostimulants and opioids, measured by either self-
administration of the drug or the conditioned place preference (CPP) paradigmiO).
 It has been reported that the ventrai tegmental area (VTA) is involved in the opioid-
induced rewarding effect. The microinjection of morphine into the VTA has been shown
to consistently produce a rewarding effect either by self-administration or CPP
paradigmii-i3).
 A great amount of evidence points to a critical role of the nucleus accumbens (N.Acc)
in mediating methamphetamine-induced rewarding effects. The microinjection of
dopamine receptor antagonists, such as (5R)-8-chloro-3-methyl-5-phenyl-2,3,4,5-
tetrahydro-IH-3-benzazepine-7-ol (SCH23390) and sulpiride, into the N.Acc. blocked
methamphetamine-induced place preferencei4'iS.
 Taken together, these reports provide evidence that the rewarding effect induced by
drugs of abuse appears to depend, at least in part, on mesolimbic dopaminergic neuronal
actlvlty.
Dopaminergic neuron development
 Dopaminergic neurons in the mammalian brain have received substantial attention in
the past, given their fundamental role in several body functions and behaviors. Cells of
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the VTA modulate rewarding and cognitive behaviors, and their dysfunction is involved
in the pathogenesis of addictive disorders and schizophrenia. The precise time of origin
of the first postmitotic dopaminergic neurons remains a matter of debate. It has become
widely accepted that the first dopaminergic neuron is born around day embryonic day
(ED) 10.5 of mouse development'6"T. At this time, these cells are characterized by an
expression of the nuclear receptor family member Nurrl and instead should be
considered as postmitotic dopaminergic precursors, since these are not yet fully
differentiated dopaminergic neuronsi8). In a strict sense, as soon as these precursors start
expressing the rate-limiting enzyme for dopaminergic synthesis, tyrosine hydroxylase
(TH), they can be considered capable of synthesizing dopamine and thus being truly
dopaminergic neurons. This happens 1 day later in embryonic development at EDI1.5 in
the mousei8). Dopaminergic neurogenesis peaks at around day ED12.5 of mouse
development and declines thereafter'9'20). Migration of the dopaminergic neurons to their
final positions in the ventral mesencephalon and innervation of their target fields takes
place during the first postnatal weeks. In the rat, this aspect of dopaminergic neuron
development, which can also be considered as "maturation" of the dopaminergic system,
appears to be finished around the third postnata1 week2'). At this time, the dopaminergic
system has acquired its adult morphology and functionality Several reports indicated
that enormous factors, such as LIM homeobox transcription factor 1alb (Lmxlalb),
transforming growth factor ctIP (TGFct/P), sonic hedgehog (Shh), fibroblast growth
factors (FGFs), Wnt family, Nurr-1, retinoid receptors (RXRs), paired- and
homeodomain-containing transcription factor (Pax) family, and trophic factors play
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critical roles of induction, specification, terminal differentiation, and maintenance in the
dopaminergic neuron development22-as).
Astrocytes
 There are two categories of cells in the CNS; neurons and adjacent glial cells,
including astrocytes, microglia, and oligodendrocytes. Cell interactions are obviously
the basis of function of the nervous system as much as of any other body system. It was
thought for a long time that the relevant cell interactions for brain function were those
of neurons with other neurons. Now it is more and more evident that taking into
consideration the interactions of neurons with glial cells is essential in understanding
how the brain works. Neuron-glia cross talk appears to be fundamental for the most
basic phenomenon in the nervous system, that is, the transfer of information by
chemical synapses26). Astrocytes are the principal type of glial cell and are known to
support the proliferation, survival, and maturation of developing neurons. It is not an
exception in the dopaminergic neurons. Li et al. reported that the activation of
dopamjne receptors in astrocyte promotes the survival of dopaminergic neurons2D.
Moreover, Johansson and Stromberg reported that astrocytes play a major role in long-
term dopaminergic outgrowth, both in axonal elongation and in the branching of
neuritis28).
5
                           Aim and Scope
 The aim of the present study is to clarify the influence of chronic exposure to an
endocrine disruptor, bisphenol-A, on the central nervous system in mice. In my
experimental approach, behavioral, neurochemical, and biochemical analysis were
performed. The specific aims of the proposed research follow.
Chapter 1:
 To ascertain the influence of in vitro treatment with low-dose bisphenol-A, I
investigated whether in vitro treatment with low-dose bisphenol-A could affect the
morphology of astrocytes in mouse-purified midbrain astrocytes and neuron/glia
cocultures. Furthemiore, I also explored the difference between bisphenol-A and 17P-
estradiol on the astrocytic and neuronal responses.
Chapter 2:
 To ascertain the relationship between the developmental toxicity of bisphenol-A and its
exposure period, the morphine-induced hyperlocomotion and rewarding effect were
examined in mice chronically exposed to bisphenol-A during several developing
periods.
Chapter 3:
 To clarify the effect of bisphenol-A on dopaminergic neuron development, l
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investigated whether prenatal exposure to it could produce morphological change in
dopaminergic neurons and the pattern of expression of genes regulating dopaminergic
neuron development. Furthermore, I also explored whether prenatal and neonatal
exposures to bisphenol-A induces astrocytic activation associated with the alternation of
the dopaminergic neuron development.
Chapter 4:
 On the endocrine-disrupting chemical problems, the low-dose effects are serious
problems. I investigated whether dopaminergic Reurotransmission could be induced by
prenatal and neonatal exposures to bisphenol-A at a lower dosage than "Lowest
Observed Adverse Effect Level."
Chapter 5:
 Since the action site of bisphenol-A remained unclear, it is most likely that prenatal
and neonatal exposures to bisphenol-A induces other behavioral abnormalities
associated with the alternation of not only the dopaminergic system, but also other
neurotransmissions. The present study was then undertaken to investigate whether
prenatal and neonatal exposures to bisphenol-A could alter other behavioral
abnormalities, such as anxiogenic behavior, motor learning behavior, and memory.
7
Ethics
  The present study was conducted in accordance with the Guiding Principles for the
Care and Use of Laboratory Animals, as adopted by Committee on Animal Research of
Hoshi University, which is accredited by the Ministry of Education, Culture, Sports,
Science and Technology of Japan. Every effort was made to minimize the numbers
and any suffering of animals used in the following experiments. Animals were used
only once in the present study.
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Chapter 1
Dynamic changes in dopaminergic neurotransmission induced by a low
concentration of bisphenol-A in neurons and astrocytes
9
Introduction
 Many toxic stimuli activate astrocytes as determined by morphological changes and by
an increase in the levels of glial fibrillary acidic protein (GFAP), which is a marker of
astrocytes29'30). The activation of astrocytes may control the structural and functional
plasticity of synapses in the central nervous systems (CNS). It has been reported that
long-term exposure to drugs of abuse can induce neuronal plasticity3"32), and Narita et al.
reported that the treatment of mouse cortical neuron/glia cocultures with drugs of abuse,
such as methamphetamine and morphine, caused morphological changes in astrocytes33).
Moreover, treatment with methamphetamine increased the sensitivity of astrocytes to
dopamine, which is responsible for the rewarding effects of psychostimulants and
opioids33). Taken together, these findings indicate that astrocytes may play an important
role in the development of dependence on drugs of abuse. It has also been reported that
they play a critical role in the survival, differentiation, pharmacological activity, and
resistance to the lesion of dopaminergic neurons.
 Recently, although several reports suggest that bisphenol-A may affect dopaminergic
signaling in the CNS'-9), little is known about its role in neuron-astrocyte
communication. The purpose of the present study is to clarify its effect on neuron-glia
communication. I used mouse midbrain neuron/glia cocultures and purified astrocytes to
determine the effects of bisphenol-A on the mesolimbic dopamine system.
 Because the sex steroid hormones estrogens and androgens have been shown to exert
profound effects on brain differentiation, neural plasticity, and central
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neurotransmission34'35), and because bisphenol-A has an affinity for estrogen receptors,
albeit 1:2000 that of 176-estradio136), I also investigated the effect of 17P-estradiol on
the astrocytic and neuronal responses.
11
Materials and methods
Tissue Processing
 Purified midbrain astrocytes were grown as follows. Midbrains were dissected from
ICR mice at postnata1 1 day (Tokyo Laboratory Animals Science, Tokyo, Japan),
minced, and treated with trypsin (O.025 9o, Invitrogen, Grand Island, NY, USA)
dissolved in phosphate-buffered saline (PBS) solution containing O.02 9o L-cysteine
monohydrate (Sigma-Aldrich, St Louis, MO, USA), O.5 9o glucose (Wako Pure
Chemicals, Osaka, Japan) and O.02 9o bovine serum albumin (Wako Pure Chemicals).
After enzyme treatment at 37 OC for 15 min, the cells were dispersed by gentle
trituration, collected and centrifuged (20 min, 1,OOO x g). After the centrifugation, cells
were plated in a flask (75 cm2 culture flask, Corning Inc, Corning, NY, USA). Seven
days after seeding in Dulbecco's modified Eagle's medium (DMEM, Invitrogen)
supplemented with 5 9o precolostrum newborn calf serum (FBS, Invitrogen), 5 9o heat-
inactivated (56 eC, 30 min) horse serum (HS, Invitrogen), 10 U/mL penicillin and 10
geglmL streptomycin in a humidified atmosphere of 95 9o air and 5 % C02 at 37 eC, the
flask was shaken for 12 hr at 37 eC to remove non-astrocytic cells. After 7 days from
seeding, the cells were seeded at a density of 1 x 105 cells/cm3, and maintained for 7
days in DMEM supplemented with 5 9o FBS, 5 9o HS, 10 U/mL penicillin and 10'5
glmL streptomycin in a humidified atmosphere of 95 9o air and 5 9o C02 at 37 eC.
 Midbrain neuronlglia co-cultures were grown as follows. Midbrains were obtained
from newborn ICR mice at postnata1 1 day, minced, and treated with papain (9 UlmL,
                                  12
Worthington Biochemical, Lakewood, NJ, USA) dissolved in PBS solution containing
O.02 9o L-cysteine monohydrate, O.5 9o glucose and O.02 9o bovine serum albumin.
After enzyme treatment at 37 eC for 15 min, the cells were dispersed by gentle
trituration, collected and centrifuged (10 min, 1,OOO x g). The cells were then seeded at
a density of 2 x 106 cells/cm3. The cells were maintained for 7 days in DMEM
supplemented with 10 9o FBS, 10 U/mL penicillin and 10 ptg/mL streptomycin.
Drug treatment and immunohistochemistry
 At 8 days after seeding, in vitro, the cells were treated with either normal medium or
medium containing bisphenol-A (10 fM - 1 pM, Wako Pure Chemicals) or 1, 3, 5 [10]-
estratriene--3,17P-diol (17P-estradiol; 10 fM - 1 pM, Sigma-Aldrich) for 24 hr. To
explore role for steroid hormone receptors in mediating the effects of bisphenol-A (1
pM, 24 hr), cells were pre-treated with either an estrogen receptor antagonist 7ct,17P-
[9[(4,4,5,5,5-pentafluoropentyl)sulfinyl]-nonyl]estra-1,3,5(10)-triene-3,17-diol
(ICI182,780; 1oo nM, 1 pM or 2 ptM, Tocris-Cookson, Ellisville, MO, USA), an
estrogen receptor agonistiantagonist tamoxifen (100 nM, 1 ptM or 10 ptM, Sigma-
Aldrich), a progesterone receptor antagonist mifepristone (100 nM, 1 ptM or 10 ptM,
Sigma-Aldrich) or an androgen receptor antagonist flutamide (100 nM, 1 ptM or 10 ptM,
Sigma-Aldrich) for 24 hr. Cells were then treated with normal medium or bisphenol-A
(1 pM) with or without these steroid hormone receptor ligands for an additional 24 hr.
Glial cells were then identified by immunofluorescence using mouse anti-glial fibrillary
acidic protein antibody (GFAP; 1:1000, Chemicon Inc., Temecula, CA, USA) followed
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by incubation with Alexa 488-conjugated goat anti-mouse IgG (1:4000). Images were
collected using a Radiance 2000 laser-scanning microscope (Radiance 2000: BioRad
Laboratories, CA, USA).
 The intensity of GFAP-like immunoreacivity was measured with a computer-assisted
system (NIH image). The upper and lower threshold intensity ranges were adjusted to
encompass and match the immunoreactivity to provide an image with immunoreactive
material appearing in black pixels, and non-immunoreactive material as white pixels.
The area and intensity of pixels within the threshold value representing
immunoreactivity were calculated. I randomly chose 10 areas (80 x 80 pixels) for
calculation of GFAP-like immunoreactivity in each image (512 x 512 pixels). The
experiments were repeatedly performed by, at least, three independent culture
preparations. The intensity of GFAP-like immunoreactivity was expressed as a percent
increase (mean Å} SEM) with respect to that in control cells, which were seeded on the
same plate.
 To evaluate the apoptotic neuronal cell death, mouse midbrain neuron/giia co-cultures
were treated with normal medium, bisphenol-A (l pM, 1 nM or 1 ptM) or 17P-estradiol
(1 pM, 1 nM or 1 yM) for 24 hr. The cells were then identified by immunofluorescence,
using rabbit-anti-cleaved caspase-3 antibody (1:100, Cell Signaling Technology Inc.,
Beverly, MA, USA), followed by incubation with Alexa 488 conjugated goat anti-rabbit
IgG (1:10000). Images were collected using a Radiance 2000 (BioRad Laboratories).
Confocal Ca2' imaging
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 Confocal Ca2' imaging was conducted according to previously reports. Mouse
midbrain neuronlglia cocultures or purified astrocytes were incubated for 24 hr with
normal medium or medium containing bisphenol-A (1 pM). Cells were then loaded with
10 ptM FIuo-3 acetoxymethyl ester (Dojindo Molecular Technologies, Kumamoto,
Japan) during incubatioR for 90 min at room temperature. After a further 20-30 min of
de-esterification with the acetoxymethyl ester, the cells which seeded on coverslips
were mounted on a microscope equipped with a confocal Ca2' imaging system
(Radiance 20oo, Bio-Rad, Rjchmond, CA, USA). Fluo-3 was excited with the 488 nm
line of an argon-ion laser and the emitted fluorescence was collected at wavelengths År
515 nm, and average baseline fluorescence (Fo) of each cell was calculated. To
compensate for the uneven distribution of Fluo-3, self-ratios were calculated (Ratio: Rs
= F/Fo). The amplitude was determined by subtracting the average of baseline
fluorescence ratio (Fb,,.ilFo) from the maximum of fluorescence ratio after a drug
treatment (F../Fo). Dopamine (1, 10 or 1oo yM, Sigma-Aldrich) was perfused via a
plastic tube for 30 sec at 5 mL/min at room temperature in cultured cortical neurons or
astrocytes followed by superfusion of basal salt solution (BSS, pH 7.4) containing 150
mM of NaCl, 5 mM of KCI, 1.8 mM of CaCl,, 1.2 mM of MgCl,, 25 mM of N-2-
hydroxyethylpiperazine-N'-2-ethaneslufonic acid and 10 mM of D-glucose.
Statistical analysis
 The data of GFAP-like immunoreactivity and confocal Ca2'
the mean Å} SEM. The statistical significance of differences
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imaging are presented as
between the groups were
assessed by one-way ANOVA with Bonferroni/Dunnett's test
16
                                Results
A low concentration of bisphenol-A, but not 17P-estradiol, causes the activation of
astrocytes
 To ascertain the effect of bisphenol-A in mouse purified midbrain astrocytes, I
performed immunohistochemical staining with a polyclonal antibody for GFAP.
Mouse midbrain purified astrocytes were treated with either normal medium or
bisphenol-A (10 fM, 100 fM or 1 pM) for 24 hr. Treatment with bisphenol-A (1oo fM, 1
pM,) for 24 hr caused a robust activation of mouse purified midbrain astrocytes, as
detected by a stellate morphology and an increase in the levels of GFAP-like
immunoreactiviry (***p Åq O.oo1 vs. control cells, Fig. 1-IA, B).
 Unlike bisphenol-A, treatment with 17P-estradiol (10 fM - 1 pM, 24 hr) failed to
produce morphological changes in midbrain astrocytes at all concentratjons tested (Fig.
1-IC, D).
 I next explored the effect of bisphenol-A on mouse midbrain neuron/glia cocultures. In
this culture system, numerous glial cells, especjally astrocytes, surround neurons.
Mouse midbrain neuron/glia cocultures were treated with either normal medium or
bisphenol-A (10 fM - 1 pM) for 24 hr. Treatment with bisphenol-A (100 fM or 1 pM, 24
hr) caused a robust activatjon of astrocytes in midbrain neuronlglia cocultures ("p Åq
O.05, **" p Åq O.OOI vs. control cells, Fig. 1-IE, F), whereas treatment with 17P-
estradiol (10 fM - 1 pM) failed to produce an increase in GFAP-like immunoreactivity
in mouse midbrain neuron/glia cocultures at any doses tested (Fig. 1-IG, H).
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Enhancement of dopamine-induced Ca2' responses by a low concentration of
bisphenol-A
 Dopamine (1-100 ptM) produced a transient increase in the intracellular Ca2'
concentration in mouse purified midbrain astrocytes (Fig. 1-2). The Ca2' responses to
dopamine (100 ptM) in astrocytes were significantly enhanced by pre-treatment with a
low concentration of bisphenol-A (1 pM, 24 hr, '"p Åq O.Ol vs. control cells, Fig. 1-2A,
B).
                                '
 On the basis of morphological appearance, neuron-like cells were selected for the Ca2'
imaging studies. Under these criteria, dopamine (1-100 ptM) produced a transient
increase in the intracellular Ca2' concentration in cultured midbrain neuron-like cells
(Fig. 1-2C, D). These Ca2' responses were significantly enhanced by treatment with a
low concentration of bisphenol-A (l pM, 24 hr, *p Åq O.05, **p Åq O.Ol, ***p Åq O.OOI vs.
coRtrol cells, Fig. 1-2C, D).
Effects of steroid hormone antagonists on the activation of astrocytes induced by a
low concentration of bisphenol-A
 To explore the involvement of steroid hormone receptor-dependent signalling in the
activation of astrocytes, I next investigated whether steroid hormone antagonists could
affect the bisphenol-A-induced increase in GFAP expression in midbrain astrocyte or
neuronallglial cultures. The highly selective estrogen receptor antagonist ICI182,780
(100 nM, 1 ptM, 2 ptM) was administered as pretreatment (24 hr) and cotreatment (24
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(100 nM, 1 ptM, 2 ptM) was administered as pretreatment (24 hr) and cotreatment (24
hr) with a low concentration of bisphenol-A (1 pM) in both mouse purified midbrain
astrocyte and neuronlglia cocultures. ICI182,780 failed to attenuate the activation of
astrocytes induced by a low concentration of bisphenol-A (1 pM, Fig. 1-3A).
Pretreatment (24 hr) aRd cotreatment (24 hr) with either the estradiol receptor
agonistlantagonist tamoxifen (100 nM, 1 ptM or 10 ptM), the progesterone receptor
antagonist mifepristone (100 nM, 1 ptM or 10 ptM) or the androgen receptor antagonist
flutamide (100 nM, 1 ptM or 10 pM) failed to affect the activation of astrocytes induced
by a low concentration of bisphenol-A (1 pM) in both mouse purified midbrain
astrocytes (Fig. 1-3C, D, E) and neuron/glia cocultures (Fig. 1-3F, G, H). These results
suggest that activation of astrocytes by a low concentration of bisphenol-A was not
mediated via estrogen receptors, progesterone receptors or androgen.
Bisphenol-A -induced neuronal cell death
 I next investigated whether in vitro treatment with either bisphenol-A or 17P-estradiol
could induce neuronal cell death. Treatment with a high concentration, but not a low
concentration, of bisphenol-A in mouse midbrain neuronlglia cocultures caused the
robust activation of caspase-3, which is a marker of neuronal cell death (Fig. 1-4).
Unlike bisphenol-A, a high concentration of 176-estradiol failed to produce caspase-3
activation (Fig. 1-4).
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Discussion
 Growing evidence suggests that astrocytes are important modulators of synaptic
transmission. They can respond to neurotransmitters released within the synapse by
generating elevations in intracellular Ca2' concentration and releasing glutamate andlor
ATP that signal back to neurons3'38). Therefore, it is worthwhile to determine the effects
of bisphenol-A on astrocytes. In the present study, I investigated the changes in
dopaminergic transmission in neurons and astrocytes induced by bisphenol-A. I show
here for the first time that in vitro treatment with bisphenol-A caused morphological
changes in GFAP-positive astrocytes. Inoue et al. previously reported that the
concentration of bisphenol-A was O.32 ng/mL (approximately 1.4 pM) in normal human
serum39). According to this report, it seems quite 1ikely that the amounts of bisphenol-A
humans are exposed to results in the exposure of astrocytes to concentrations greater
than 1 pM.
 Neurons and astrocytes respond to various and chemical stimuli, including
neurotransmitters, neuromodulators, and hormones, with an increase in the intracellular
Ca2+ concentration. These Ca2'responses result from the coordinated activity of several
molecular cascades responsible for Ca2'movement into or out of the cytoplasm by way
of either the extracellular space or intracellular stores. I have demonstrated here that the
dopamine-induced Ca2' responses in mixed cultures of neurons and astrocytes were
significantly enhanced by treatment with a low concentration of bisphenol-A (1 pM, 24
hr). These findings strongly support the idea that the enhancement of Ca2' responses to
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dopamine induced by a low concentration of bisphenol-A could lead to an increase in
the excitability of central dopaminergic neurotransmission.
 It has been reported that the stimulation of dopamine Di receptor increased the
intracellular Ca2' concentration via the activation of the phospholipase C-inositol-1,4,5-
triphosphate signaling pathway40'`i). Dopamine-induced Ca2' responses are also
modulated by a dopamine D2 receptor`2'`3). On the other hand, the dopamine D3 receptor
normally coexists with dopamine Di and D2 receptors"), which contribute to the
inhibitory modulation of dopamine Di andlor D2 receptor-mediated signaling`S. Also,
it has been reported that prenatal and neonatal exposures to bisphenol-A enhanced
central dopamine Di receptor function7) and attenuated dopamine D3 receptor function in
mice9). Thus the present data suggest that treatment with 1 pM of bisphenol-A may
enhance the dopamine D, receptor function andlor attenuate the dopamine D3, receptor
function, resulting in an enhancement of the dopamine-induced Ca2' response in
neurons and astrocytes.
 As mentioned above, many toxic stimuli activate astrocytes29'30). I next investigated
whether the astrocytic activation was associated with neurotoxicity. In the present study,
treatment with a high (1 pM) concentration of bisphenol-A markedly induced neuronal
cell death in midbrain neuronlglia cocultures. Treatment with a low concentration (1
pM) did not. Therefore the astrocytic activation mediated by treatment with a low
concentration of bisphenol-A was associated without neurotoxicological action,
probably with the pharmacological action of bisphenol-A.
 It has been reported that prenatal and neonatal exposures to bisphenol-A induced the
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potentiation of dopamine receptor functions in the mouse limbic area, resulting in
supersensitivity to methamphetamine- and morphine-induced pharmacological
actions7'9). My findings suggest that the enhancement of dopaminergic transmission in
neurons and astrocytes induced by bisphenol-A may, at least in part, lead to an
enhancement of the development of psychological dependence on drugs of abuse.
 Bisphenol-A can modulate gene transcription and numerous biological changes via
estrogenic receptors36'`6'`'). It has been reported that equal doses of bisphenol-A and 17P-
estradiol could activate the transcription factor cAMP-responsiye element-binding
protein (CREB) via nonclassical estrogen receptor, resulting in the transcriptional
activation of CREB-responsive genes48). On the other hand, obvious differences between
bisphenol-A and 17P-estradiol have been also reported. For example, 17P-estradiol at
10 nM reduced the duration of Ca2' oscillations in mouse oocytes, whereas
concentrations of bisphenol-A as high as 100 ptM were necessary for similar inhibition`9).
It has been reported that 17P-estradiol inhibits the astrocytic uptake of glutamate, which
is the most important excitatory neurotransmitter in the CNS, whereas bisphenol-A has
no such effect50). Taken together, these observations suggest that bisphenol-A and 17P-
estradiol may be coupled to different signaling cascades in the CNS.
 It has been reported that astrocytes are among the most important target cells for 17P-
estradiol. In fact, they express all types of estrogen receptors during development and in
the adult brainsu52). In the present study, however, neither the estrogen receptor
antagonist ICI182,780 nor the estrogen receptor agonistiantagonist tamoxifen failed to
block the activation of astrocytes induced by bisphenol-A. The progesterone receptor
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antagonist mifepristone and the androgen receptor antagonist flutamide also had no
effect on the activation of astrocytes induced by bisphenol-A. Furthermore, 17P-
estradiol had no effect on the activation of astrocytes in purified astrocytes or
neuron/glia cocultures. It seems very likely that estrogen receptors and other steroid
hormone receptors may not be critical for the activation of astrocytes induced by
bisphenol-A.
 In conclusion, the present data provide evidence that in vitro treatment with a low
concentration of bisphenol-A induces dopaminergic amplification in neurons and
astrocytes without steroid-hormonergic effects. These effects may contribute to
potentiate the development of the rewarding effect of drugs of abuse in mice prenatally
and neonatally exposed to bisphenol-A. Further in vivo investigation is necessary to
fully understand the role of astrocytes in the potentiation of the dopaminergic
neurotransmission in mice prenatally and neonatally exposed to bisphenol-A. As
mentioned above, it has been reported that astrocytes play a critical role in the survival,
differentiation, pharmacological activity, and resistance to the lesion of dopaminergic
neurons. Thus it is possible that the astrocytic activation induced by exposure to
bisphenol-A affect not only the dopaminergic neurotransmission, but also such things as
dopaminergic neuron development.
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                            Chapter2
Changes in central dopaminergic systems and morphine reward by prenatal and
neonatal exposures to bisphenol-A in mice: Evidence of the importance of the
exposure period
28
Introduction
 It has been reported that administrations of bisphenol-A to pregnant mice on gestation
days in doses within the range typical of the environmental exposure of humans
produces significant changes in the postnatal growth rate and brings on early puberty in
these mice5). Bisphenol-A also inhibits the differentiation of oligodendrocyte precursor
cells induced by exposure to the thyroid hormoneS3). These results support the idea that
bisphenol-A may cause toxicity in the developmental process. Also, recent findings
demonstrated that prenatal and neonatal exposures to bisphenol-A markedly enhance the
rewarding effects induced by drugs of abuse, such as methamphetamine7) and
morphine8). Furthermore, prenatal and neonatal exposures to bisphenol-A enhances
central dopamine Di receptor function7) and attenuates dopamine D3 receptor function9)
in mice. These findings indicate that exposure to bisphenol-A may cause alterations in
dopaminergic neurotransmission in the central neryous system (CNS), resulting in the
enhancement of drug rewards. The aim of the present study was to further investigate
the relationship between the effects of bisphenol-A on dopamine-related behaviors and
the bisphenol-A exposure period, and to determine the most sensitive period in prenatal
and neonatal exposures to bisphenol-A in mice.
29
Materials and methods
Animals
 All experiments were performed using male ddY mice that had been prenatally and
neonatally exposed to bisphenol-A (Wako Pure Chemical Industries Ltd., Osaka, Japan).
Adult female mice were chronically treated with bisphenol-A-admixed powder food
containing O (control), 2 pg bisphenol-Alg of food during the period of implantation (I-
2; embryonic days [EDs] O-7), organogenesis (O-2; EDs 7-14), parturition (P-2; EDs
14-20) and lactation (L-2 posMatal days O-20). Their pups were prenatally and
neonatally exposed to the respective concentration of bisphenol-A from their mothers.
During the treatment with bisphenol-A, animals did not show weight loss or disrupted
maternal behaviors. In addition, the pups did not show weight loss or decrease of birth
rate. All experiments used mice aged 7-9 weeks.
Measurement of locomotor activity
 The locomotor activity of mice was measured by an ambulometer according to
previous report 5`). Briefly, a mouse was placed in a tilting-type round activity cage 20
cm in diameter and 19 cm high. Any slight tilt of the activity cage, which was caused by
horizontal movement of the mouse, was detected by three microswitches. Total activity
counts were automatically recorded for 3 hr following the injection of saline (10 mLlkg,
s.c.) or morphine (10 mg/kg, s.c.; Sankyo Co., Tokyo, Japan).
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Place conditioning
 PIace conditioning was conducted according to previous reports 55'56). The apparatus
was a shuttle box (15 x 30 x 15 cm: w x 1 x h), which was made of an acrylic resin
board and divided into two equal-sized compartments. One compartment is white with a
textured floor, and the other is black with a smooth floor to create equally preferred
compartments. For conditioning, mice were confined to one compartment after drug
injections and to the other compartment after saline injection. The order of the injection
(drug or vehicle) and compartment (white or black) was counterbalanced across subjects.
Conditioning sessions (three days for morphine, three days for saline) were conducted
once daily for six days. Immediately after s.c. injection of morphine (1 mg/kg), animals
were placed in one compartment for 1 hr. On alternate days, animals receiving yehicle
were placed in the other compartment for 1 hr. On day seven, tests of conditioning were
performed as follows. The partition separating the two compartments was raised to 7 cm
above the floor, and a neutral platform was inserted along the seam separating the
compartments. The mice were not treated with either morphine or saline, and then
placed on the platform. The time spent in each compartment during a 900-sec session
was then recorded automatically using an infrared beam sensor (KN-80, Natsume
Seisakusyo Co., Tokyo, Japan). The preference for drugpaired place was shown as a
mean difference between the time spent during the drug-conditioning compartment and
saline-conditioning compartment. All sessions were conducted under conditions of dim
illumination (28 lux lamp) and white masking noise.
31
[35S]GTPyS binding assay
 In the membrane preparation, mice were killed by decapitation and the limbic
forebrain was then dissected according to previous report 56). The limbic forebrain was
rapidly excised at 4 eC, and the tissues were homogenized using a Potter-Elvehjem
tissue grinder with a Teflon pestle in 20 volumes (w/v) of ice-cold Tris-Mg2" buffer
containing 50 mM Tris-HCI (pH 7.4), MgCl, and 1 mM EGTA for the t35SIGTPyS
binding assay. The homogenate was centrifuged at 4 OC for 10 min at 48,OOO x g. The
pellet was resuspended in [35S]GTPyS binding assay buffer containing 50 mM Tris-HCI
(pH 7.4), 5 mM MgCl,, 1 mM EGTA, and 100 mM NaCl and centrjfuged at 4 OC for 10
min at 48,OOO x g. The resultant pellet was resuspended in [35SIGTPyS binding assay
buffer and stored at -70 OC until used. The membrane homogenate (3-8 ptg
protein/assay) was incubated at 25 OC for 2 hr in 1 mL of assay buffer with various
concentrations of dopamine (Sigma-Aldrich, St Louis, MO, USA), 30 ptM guanosine-
5'-diphosphate (GDP) and 50 pM t35S]GTPyS (specific activity, 1000 Cilmmol;
Amersham, Arlington Heights, IL, USA). The reaction was terminated by filtration
using a Brandle cell harvester and Whatman GF/B glass filters presoaked in 50 mM
Tris-HCI (pH 7.4) and 5 rnM MgCl, at 4 eC for 2 hr. Filters were then washed three
times with 5 mL of an ice-cold Tris-HCI bufifer (pH 7.4), transferred to scintillation
counting vials containing O.5 mL of Soluene-350 (Packard Instrument Company,
Meriden, CT, USA) and 4 mL of Hionic Fluor (Packard Instrument Company),
equilibrated for 12 hr, and the radioactivity in the samples was determined with a liquid
scintillation analyser. Non-specific binding was measured in the presence of 10 ptM
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unlabeled GTPyS.
Statistical analysis
 Data represent the mean counts with SEM. Statistical analyses were performed using
one-way ANOVA with Bonferroni!Dunnett's test.
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Results
Enhancement of morphine-induced hyperlocomotion in mice exposed to bisphenol-
A during the organogenesis or lactation period
 Treatment with 10 mglkg (s.c.) of morphine produced a locomotor-enhancing effect in
all groups. In both O-2 and L-2 mice, but not I-2 and P-2, the hyperlocomotion induced
by morphine was dramatically potentiated as compared to that in control (pÅqO.05 vs.
control, Fig. 2-1).
Enhancement of morphine-induced rewarding effect in mice exposed to bisphenol-
A during the organogenesis or lactation period
 At the dose of 1 mglkg, morphine produced neither place preference nor place aversion
in control, I-2 and P-2 mice. However, treatment with 1 mglkg of morphine produced a
significant place preference in both O-2 and L-2 (pÅqO.05 v.s. control, Fig. 2-2).
The dopamine-induced G-protein activation in the limbic forebrain of mice
exposed to bisphenol-A during the organogenesis or lactation period
Dopamine (O.1-10 mM) produced a concentration-dependent increase in [35S]GTPyS
binding to membranes from the limbic forebrain including the nucleus accumbens of
control, I-2, O-2, P-2 and L-2 mice. It should be noted that the stimulation of
[35SIGTPyS binding induced by dopamine was markedly potentiated in O-2 and L-2
mice (Fig. 2-3).
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Discussion
 Drug addiction is a pathological behavior characterized by compu}sive drug seeking
and drug ingestion despite severe adverse consequences. The place-conditioning
paradigm has become the most frequently used method to evaluate the motivational
properties, and its use has been reported more frequently than the self--administration
paradigm.
 Many studies have suggested that the mesolimbic dopaminergic system, which
projects from the ventral tegmental area (VTA) to the nucleus accumbens, is critical for
the initiation of opioid reinforcement and hyperlocomotion5'-59). Either
Tyr-D-Ala-Gly-[N-Me-Phe]-NH(CH,),-OH (DAMGO)- or morphine-induced place
preference can be blocked by dopamine receptor antagonists60'6i). Moreover,
hyperlocomotion induced by morphine can be blocked by treatment with dopamine
receptor antagonists in the nucleus accumbens62'63). These findings indicate that the
dopamine-containing neuron of the midbrain VTA, which has a high density of
pt-opioid receptors, plays a critical role in the rewarding effects and hyperlocomotion by
pt-opioid receptor agonists. In terms of dopamine receptor involvement at the terminal
site of the mesolimbic dopamine system, the rewarding effects of an abused drug have
been shown to be mediated by dopamine Di receptors5`'6i). Also, the dopamine D,
receptor cloned by Sokoloff and colleagues has been characterized extensively6`). The
dopamine D3 receptor shows a distinct distribution in limbic areas of the brain,
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olfactory tubercle6`). Several pharmacological studies with dopamine D3 receptor-
prefening agonists, such as 7--hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT),
suggest that the dopamine D3 receptor regulates the inhibitory effect to produce
hyperlocomotion in rodents65'66). Furthermore, Narita et at. reported that the morphine-
induced rewarding effect and hyperlocomotion were markedly enhanced in mice lacking
the dopamine D3 receptor gene7). These findings suggest that the dopamine D3 receptor
plays a critical role in mediating drug-induced effects on dopamine neurotransmission.
 Recent studies showed that prenatal and neonatal exposures to bisphenol-A enhance
the rewarding effects of drugs of abuse, which are associated with the up-regulation of
central dopamine Di receptor functions and the down-regulation of the functional
dopamine D3 receptors in mice"9). In the present study, I investigated the relationship
between these neuronal changes and the exposure period for bisphenol-A. The exposure
to bisphenol-A during either organogenesis or lactation significantly enhanced the
morphine-induced hyperlocomotion and rewarding effect. These findings suggest that
prenatal and neonatal, especially organogenetical and lactational exposures to
bisphenol-A, lead to the supersensitivity of the drugs of abuse-induced pharmacological
actlons.
 Morphine has been shown to indirectly activate dopamine neurons in the VTA as a
consequence of inhibiting nondopaminergic neurons, presumably y-aminobutyric acid
(GABA)-containing neurons, leading to an increased dopamine release in the nucleus
accumbens. Mizuo et al. reported that prenatal and neonatal exposures to bisphenol-A
failed to enhance p-opioid receptor-mediated G-protein activation by morphine in the
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lower midbrain8). Moreover, the expression of p-opioid receptor mRNA was not
changed by chronic bisphenol-A treatment, suggesting that p-opioid receptor function is
unaffected in this region8). Therefore I next investigated the influence of prenatal and
neonatal exposures on bisphenol-A in the mesolimbic dopaminergic function using
[35S]GTPyS binding assay. The exposure to bisphenol-A during either organogenesis or
lactation also produced an up-regulation of dopamine receptor function to activate G-
protein in the mouse limbic forebrain. These results indicate that either organogenesis or
lactation is more sensitive to the bisphenol-A--induced neuronal toxicity than any other
periods such as implantation and parturition.
 Recently, several investigations have provided evidence that the treatment of adult
animals with bisphenol-A could not affect the reproductiye function or social
behaviors6"os). I have already confirmed that the acute administration of bisphenol-A
with adult mice could not affect the dopamine-related behaviors (data not shown). On
the other hand, several investigations clarified the behavioral abnormalities by prenatal
and neonatal exposures to bisphenol-A. These findings indicate that prenatal and
neonatal exposures to bisphenol-A may cause neuronal toxicity specifically in the
developmental process. In the present study, I focused on the relationship between these
developmental changes and the exposure period for bisphenol-A. The exposure to
bisphenol-A during either organogenesis or lactation significantly enhanced the
morphine-induced hyperlocomotion and rewarding effect. Furthermore, the exposure to
bisphenol-A during either organogenesis or lactation also produced an up-regulation of
dopamine receptor function to activate G-protein in the mouse limbic forebrain. These
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results indicate that either the period of organogenesis or of lactation is more sensitive
to the bisphenol-A-induced developmental toxicity than any other period is.
 Generally, it is well known that in cerebral development the proliferation,
differentiation, or migration of nerve cells and glia cells is carried out most briskly at
organogenesis69). Furthermore, the functional development of the CNS, synaptogenesis,
and the construction of the nerve network are carried out most briskly at lactation69).
Therefore, these reports strongly support the present results that these periods are the
most sensitive for the influence of bisphenol-A exposure in the development of the CNS.
These results suggest that exposure to bisphenol-A during organogenesis could affect
the differentiation or migration of neuronal stem cells. Furthermore, an exposure to
bisphenol-A during lactation affects the functional development of the CNS, including
synaptogenesis and the construction of the neuronal network.
 Taken together, the present data may explain that although adult animals treated with
bisphenol-A could not affect the reproductive function and social behaviors, the prenatal
and neonatal exposures, especially either organogenesis or lactation, to bisphenol-A
induced developmental neuronal toxicity in the midbrain of rodents. AIthough further
investigation is necessary to fully understand the molecular mechanism of disruption of
dopaminergic neuron development by bisphenol-A, my findings warn that exposure to
bisphenol-A during either organogenesis or lactation may predispose their children to
the development of dopamine-related disorders.
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                            Chapter 3
Changes in central dopaminergic systems with the expression of Shh and GDNF in
mice exposed to bisphenol-A during developmental periods
42
Introduction
 It has been reported that prenatal and neonatal exposures to bisphenol-A markedly
enhanced the rewarding effects or hyperlocomotion induced by methamphetamine') and
morphine8"O). These findings indicate that exposure to bisphenol-A during development
alters the postsynaptic regulation of dopaminergic neurotransmission in the central
nervous system (CNS), which results in an enhancement of psychological dependence
on drugs of abuse. Although bisphenol-A may affect dopaminergic signaling in the CNS,
little is known about the direct role of bisphenol-A in the development of dopaminergic
neurotransmission. As described in chapter 2, exposure to bisphenol-A during
organogenesis (Embryonic days [EDs] 7--14), but not implantation (EDs O-7) or
parturition (EDs 14-20), significantly enhanced the morphine-induced hyperlocomotion
and rewarding effects. Furthermore, exposure to bisphenol-A during organogenesis also
produced an up-regulation of dopamine receptor function to activate G-protein in the
mouse limbic forebrain. It has been wildly accepted that the first dopaminergic neurons
are born around ED 10.5 of mouse development. Moreover, dopaminergic neurons of
the ventral tegmental area (VTA) are generated from approximately ED 10 to ED 142`).
Therefore, chronic treatment with bisphenol-A could disrupt dopaminergic neuron
development. The purpose of the present study was then to clarify the effect of
bisphenol-A on the dopaminergic neuron development in mice.
 Also, many recent findings have supported the idea that astrocytes, which are a
subpopulation of glial cells, play a critical role in neuronal transmission in the CNS.
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Their activation may control the structural and functional plasticity of synapses in the
CNS. On the other hand, long-term exposure to drugs of abuse can induce neuronal
plasticity, and the treatment of mouse cortical neuron/glia cocultures with
methamPhetamjne or morphine causes morphological changes in astrocytes33).
Moreover, treatment with methamphetamine increased the sensitivity of astrocytes to
dopamine, which is responsible for the rewarding effects of psychostimulants and
opioids33). Furthermore, astrocytes play a critical role in dopaminergic neuron
development. As described in chapter 1, the in vitro treatment of bisphenol-A in mouse-
purified astrocytes and neuron/glia cocultures caused the activation of astrocytes, as
detected by a stellate morphology and an increase in the levels of GFAP. Therefore, I
also inyestigated whether prenata! and neonatal exposure to bisphenol-A induces
astrocytic activation associated with the alternation of the dopaminergic neuron
development.
an
                         Materials and Methods
Animals
 All experiments were performed using 10-14 weeks old male C57BL/6J mice (Japan
SLC, Inc., Shizuoka, Japan) that had been prenatally and neonatally exposed to
bisphenol-A (Wako Pure Chemical Industries Ltd., Osaka, Japan). Adult female mice
(10 weeks old) were chronically treated with bisphenol-A-admixed powder food
containiBg zero (control), 2 x 103 ptg bisphenol-A/g of food from mating to weaning.
Their pups were prenatally and neonatally exposed to the respective concentration of
bisphenol-A from their mothers. In addition, RT-PCR was also performed using
embryonic C57BL/6J mice that had been prenatally exposed to bisphenol-A from
mating to embryo 14 days (same concentration as mentioned above).
RT-PCR
 In the RNA preparation and semiquantitative analysis by reverse transcription-PCR,
total RNA in the whole brain (adult mice: excluding cerebellum, embryonic mice:
including cerebellum) was extracted using the SV Total RNA Isolation System
(Promega, Madison, WI, USA) following the instructions of the manufacturer. First-
strand cDNA was prepared according to previous report'i), and the targeted genes were
amplified in 50 ptL of a PCR solution containing MgCl,, dNTP mix and DNA
polymerase (Invitrogen, Carlsbad, CA, USA) with synthesized primers of dopamine Di
receptor (103 bp)(sense, 5'-CTC ATA AGC TTT TAC ATC CCC G-3'; antisense,
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5'-CCC TCT CCA AAG orG AGA TG-3'), dopamine D, receptor (202 bp)(sense,
5'-CTC TAC CCT CCA ATC CAC TCC-3'; antisense, 5'-TAA GGC AGA GGC ACT
GGC3'), dopamine D, receptor (136 bp) (sense, 5'-GCA GTG GTC ATG CCA GTT
CAC TAT CAG-3'; antisense, 5'--Cer GTT GTG TTG AAA CCA AAG AGG AGA
GG -3'), DAT (540 bp)(sense, 5'-AAG ATC TGC CCT GTC orG AAA G-3';
antisense, 5'--CAT CGA TCC ACA CAG ATG CCT C-3'), Shh (243 bp) (sense,
5'--CTG GCC AGA TGT TTT CTG GT-3'; antisense, 5-GAT GTC GGG GTT GTA
ATT GG-3) or GDNF (403 bp) (sense, 5'-ACC AGA TAA ACA AGC GGC AG-3;
antisense, 5-TCA GAT ACA TCC ACA CCG T'IT AG-3'). Samples were heated to
940C for 5 min, 550C for 1 min, and 720C for 1 min, and cycled 35 times through 940C
for 30 sec, 550C for 1 min, and 720C for 1 min. The final incubation was at 720C for 7
min. The mixture was subjected to 29o agarose gel electrophoresis with the indicated
markers and primers for the internal standard glyceraldehyde-3-phosphate
dehydrogenase. Each sample was applied to more than two lanes in the same gel. The
agarose gel was stained with ethidium bromide and photographed with ultraviolet
transillumination. The intensity of the bands was analyzed and quantified by computer-
assisted densitometry using NIH Image software.
Immunohistochemistry
 In the immunohistochemical approach, mice were deeply anesthetized with sodium
pentobarbital (70 mg/kg, i.p.) and perfusion-fixed with 4% paraformaldehyde (pH 7.4).
The brains were then quickly removed after perfusion, and thick coronal sections of the
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midbrain including the ventral tegmental area (VTA) or the limbic forebrain including
the nucleus accumbens/ventral pallidum were initially dissected using Brain Blocker.
The brain coronal sections were postfixed in 49o paraformaldehyde for 2 hr. After the
brains were permeated with 209o sucrose for 1 day and 309o sucrose for 2 days, they
were frozen in embedding compound (Sakura Finetechnical, Tokyo, Japan) on
isopentane using liquid nitrogen and stored at -300C until use. Frozen 8-ptm-thick
coronal sections were cut with a cryostat (CM1510; Leica, Heidelberg, 6ermany) and
thaw mounted on poly-L-lysine-coated glass slides. The brain sections were blocked in
109o normal horse serum (NHS) iB O.OIM PBS for 1 hr at room temperature. Each
primary antibody was diluted in O.Ol M PBS containing 109o NGS [1:1000 tyrosine
hydroxylase (TH) (Chemicon, Temecula, CA, USA), 1:10 GFAP (NICHIREI, Tokyo,
Japan) and 1:2500 DAT (Chemicon)] and incubated for 2 days at 40C. The samples
were then rinsed and incubated with the appropriate secondary antibody conjugated
with Alexa 488 and Alexa 546 for 2 hr at room temperature. The slides were then
coverslipped with PermaFluor Aqueous mounting medium (Immunon, Pittsburgh, PA,
USA). Fluorescence immunolabeling was detected using a light microscope (AX-70;
Olympus Optical, Tokyo, Japan) and photographed with a digital camera (Polaroid
PDMCIIIOL; Olympus Optical).
Statistical analysis
 All data are expressed as mean Å} SEM. Statistical analyses were performed using
Student's t-test.
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Result
Down-regulation of the expression of dopamine D3 receptor, Shh and GDNF
mRNAs in the whole brain obtained from embryonic mice prenatally exposed to
bisphenol-A
 In the RT-PCR assay, chronic bisphenol-A treatment produced a significant decrease in
the dopamine D3 receptor (pÅqO.Ol, Fig. 3-IE, F), Shh (pÅqO.OOI, Fig. 3-II, J) and GDNF
(pÅqO.Ol, Fig. 3-IK, L) mRNA production in the whole brain obtained from embryonic
mice (ED 14). On the other hand, no changes in mRNA levels of Shh (Fig. 3-IM, N)
and GDNF (Fig. 3-10, P) mRNA were noted in the whole brain obtained from the adult
mice prenatally and neonatally exposed to bisphenol-A. Under these conditions, no
changes in mRNA levels of dopamine Di receptor (Fig. 3-IA, B), dopamine D2 receptor
(Fig. 3-IC, D) and DAT (Fig. 3-IG, H) were noted in the whole brain obtained from
embryonic mice.
Increases in DAT, TH and GFAP-like immunoreactivities in the nucleus accumbens
and ventral pallidum of mice prenatally and neonatally exposed to bisphenol-A
 I first investigated the possible morphological changes in dopaminergic neuron. The
DAT or TH-like immunoreactivity (DAT-IR or TH-IR) in the VTA was observed by
immunohistochemical analysis (Fig. 3-2A-D). Prenatal and neonatal exposure to
bisphenol-A failed to induce morphological changes in dopamine cell bodies or the
number of dopaminergic neuron. On the other hand, prenatal and neonatal exposure to
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number of dopaminergic neuron. On the other hand, prenatal and neonatal exposure to
bisphenol-A produced a dramatical increase in the levels of DAT-IR and TH-IR in the
nucleus accumbens (Fig. 3-2E-H). In addition, GFAP-1ike immunoreactivity (GFAP-IR)
was increased in the mouse ventral pallidum by prenatal and neonatal exposure to
bisphenol-A (Fig. 3-2I, J). Double-labelling experiments showed that the increased
DAT-IR was expressed in nonglial cells of the nucleus accumbens obtained from
bisphenol-A treated mice, as shown by no apparent colocalization with GFAP-IR (Fig.
3--2K, L).
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Discussion
 Recently, several investigations have provided evidence that the treatment of adult
animals with bisphenol-A could not affect the reproductive function and social
behavior6'). I found that an acute administration of bisphenol-A in adult mice faiied to
affect the dopamine-related behaviors (data not shown). On the other hand, several
investigations clarified the behavioral abnormalities by prenatal and neonatal exposure
to bisphenol-A'-9'70). These findings indicate that prenatal and neonatal exposures to
bisphenol-A may cause neuronal toxicity, specifically in the developmental process. It
has been reported that prenatal and neonatal exposure to bisphenol-A induces the
abnormality of the dopamine receptor functions in the mouse limbic area, resulting in a
supersensitivity of methamphetamine-induced pharmacological actions7). These findings
indicate that exposure to bisphenol-A during development alters the postsynaptic
regulation of dopamine neuron. In the present study, I therefore focused on the change
in the dopaminergic neuron during development.
 Here I found that chronic bisphenol-A treatment produced a significant decrease in
sonic hedgehog (Shh) and glial cell-line-derived neurotrophic factor (GDNF)
production in the whole brain obtained from embryonic mice. On the other hand, no
changes in mRNA levels of Shh and GDNF were noted in the whole brain obtained
from the adult mice prenatally and neonatally exposed to bisphenol-A. Progenitor cells
develop into dopaminergic neurons through the actions of Shh and fibroblast growth
factor 8 (FGF8)22). Maturation is orchestrated by several transcription factors, including
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the orphan nuclear receptor (Nurr-1), which is widely expressed in both the adult and
the developing CNS25). Furthermore, it was reported that Shh, FGF8, and Nurr-1
collaborate to induce dopaminergic phenotypes'2). GDNF is also one of the most potent
trophic factors for dopaminergic neurons, playing a role in development and surviva123).
Therefore the present data support the idea that prenatal and neonatal exposure to
bisphenol-A may disrupt dopaminergic neuron development associated with the
expression of Shh and GDNF.
 It has been reported that prenatal and neonatal exposure to bisphenol-A induced the
functional reduction in dopamine D3 receptors in mice9). Du et al. reported that the
pharmacological action of GDNF was regulated by the activation of dopamine D3
receptor73). As described in chapter 2, exposure to bisphenol-A during organogenesis
(EDs 7-14), but not implantation (EDs O-7) and parturition (EDs 14--20), significafitly
enhanced the morphine-induced hyperlocomotion and rewarding effect. Furthermore,
exposure to bisphenol-A during organogenesis also produced an up-regulation of
dopamine receptor function to activate G-protein in the mouse limbic forebrain. These
findings strongly support my hypothesis that bisphenol-A disrupts dopaminergic neuron
development.
 Next, I further investigated whether prenatal and neonatal exposures to bisphenol-A
could affect the dopaminergic neuron in the adult brain. Immunohistochemical study
showed that prenatal and neonatal exposures to bisphenol-A failed to change DAT-IR
and TH-IR in the VTA. These results suggest that prenatal and neonatal exposures to
bisphenol-A failed to induce cell death, overexpression, or morphological changes in
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dopaminergic neuron in the VTA. On the other hand, I found that prenatal and neonatal
exposures to bisphenol-A dramatically increased DAT-IR and TH--IR in the nucleus
accumbens. These results suggest that prenatal and neonatal exposures to bisphenol-A
induce the abnormalities at axon terminals of dopaminergic neurons.
 Another key finding of the present study was that prenatal and neonatal exposures to
bisphenol-A induced astroglial proliferation as characterized by the increase in GFAP-
IR levels, and astroglial hypertrophy as detected by a stellate morphology of GFAP-IR
in the ventral pallidum. Many toxic stimuli activate astrocytes. Their activation may
control the structural and functional plasticity of synapses in the CNS. Recent
accumulating evidence suggests that astrocytes express a repertoire of neurotransmitter
receptors mirroring that of the neighboring synapse. Such receptors are stimulated
during synaptjc actiyity and spread information by calcium signaling into the astrocyte
network via gap-junction channels'`). It has been widely accepted that the long-term
exposure to drugs of abuse can induce neuronal plasticity. Recent reports suggested that
the treatment of mouse cortical neuronlglia cocultures with methamphetamine or
morphine causes morphological changes in astrocytes33). Moreover, treatment with
methamphetamine increases the sensitivity of astrocytes to dopamine, which is
responsible for the rewarding effects of psychostimulants and opioids33). It is interesting,
as described in chapter 1, that the treatment of mouse-purified astrocytes and
neuron/glia cocultures with bisphenol-A caused the actiyation of astrocytes, as detected
by stellate morphology and an increase in the levels of GFAP. It has been reported that
the projection from the nucleus accumbens to the ventral pallidum regulates the
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reinstatement of cocaine-seeking behavior in rats extinguished from cocaine self-
administration'S. The nucleus accumbens and ventral pallidum have a pivotal role in
regulating exploratory motor behaviors. The pharmacological manipulation of
dopamine or enkephalin transmission in the nucleus accumbens induces motor activity.
The nucleus accumbens has a prominent y-aminobutylic acid (GABA)-ergic projection
to the ventral pallidum. The motor response elicited by microinjecting the pt-opioid
agonist D-Ala--Tyr-Gly-NMePhe-Gly-OH (DAMGO) or dopamine into the accumbens
is blocked by stimulating GABAA receptors in the ventral pallidum with the agonist
muscimo176). Collectively, these reports strongly support the idea that the astrocytic
activation in the ventral pallidum of mice prenatally and neonatally exposed to
bisphenol--A plays a critical role in the supersensitivity to methamphetamine following
bisphenol-A treatment.
 As mentioned above, prenatal and neonatal exposures to bisphenol-A may dramatically
change the dopaminergic transmission. Knaak and Sullivan (1966) first reported the
metabolic fate of bisphenol-A in rats'D, showing that the major metabolite in urine was
the glucuronide of bisphenol-A; considerable amounts of free bisphenol-A and
hydoxylated bisphenol-A were found in feces. Many reports have shown that bisphenol-
A is metabolized and excreted rapidly'8), and I found that its acute administration to
adult mice did not affect their dopamine-related behaviors. In my preliminary
biochemical studies, bisphenol-A did not increase or decrease [35S]GTPyS bindings to
brain membranes. AIso, I could not make the Scatchard plot using [3H]bisphenol-A in
brain membranes. Taken together, it is almost impossible that bisphenol--A remaining in
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the adult brain of mice directly affects dopaminergic neurotransmission.
 At the present time it is very hard to say where the primary action site of bisphenol-A
is. Although it has weak estrogenic activity, prenatal and neonatal exposures to 17P-
estradiol failed to induce supersensitivity to morphine (as described in chapter 4). And
as described in chapter 1, treatment with 17P-estradiol failed to induce astrocytic
activation. Furthermore, although it is well known that bisphenol-A disrupts thyroid
hormone, prenatal and neonatal exposures to propylthiouracil, a thyroid hormone
inhibitor, reduced dopaminergic neuron activation. These findings indicate that a
disruption of dopaminergic neuron development induced by prenatal and neonatal
exposures to bisphenol-A can be mediated by the nonhormonergic actions of bisphenol-
A.
 In conclusion, the present data suggest that bisphenol-A induces dopaminergic
amplification following the disruption of the dopaminergic neuron development. This
phenomenon could explain the aggravation of the development of dependence on drugs
of abuse.
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Chapter 4
Prenatal and neonatal exposures to Iow-dose bisphenol-A enhance the
morphine-induced hyperlocomotion and rewarding effects
57
Introduction
 As mentioned in previous chapters, prenatal and neonatai exposures to high-dose
bisphenol-A (2 x 103 ptg of bisphenol-A/g of food) induced dopaminergic amplification
following the disruption of the dopaminergic neuron deyelopment. However, Inoue et aL
preyiously reported that the concentration of bisphenol-A was O.32 ng/mL in normal
human serum39). According to this report, it should be mentioned that the blood level of
bisphenol-A in mjce prenatally and neonatally exposed to high-dose bisphenol-A
(approximately 10 nglmL) is considered to be more than 30 times higher than the
healthy human-exposure Ievel. Regarding endocrine disruptor problems, the low-dose
actions of endocrine disruptors are serious problems. However, little is known about its
action on the central nervous systerri induced by low-dose bisphenol-A. The present
study was then undertaken to investigate whether prenatal or neonatal exposure to low-
dose bisphenol-A in mice could affect the rewarding effects and the locomotor-
enhancing effects induced by morphine.
 Because sex steroid hormones (estrogens and androgens) have been shown to exert
profound effects on brain differentiation, neural plasticity, and central
neurotransmission34'3S, and because bisphenol-A has an affinity for estrogen receptors,
albeit 1:2000 that of 17P-estradio136), I also investigated the effect of 17P-estradiol on
the rewarding effects induced by morphine.
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Materials and Methods
Animals
 The experiments were performed using 7 weeks old male ddY mice (Tokyo Animal
Science Co., Tokyo, Japan) that had been prenatally and neonatally exposed to
bisphenol-A (Wako Pure Chemical Industries Ltd., Osaka, Japan). Adult female mice
(10 weeks old) were chronically treated with bisphenol-A-admixed powder food
containing zero (control) or 3 x 10'2 ptg bisphenol-Alg of food from mating to weaning.
Their pups were prenatally and neonatally exposed to bisphenol-A from their mothers.
During the treatment with bisphenol-A, animals did not show weight loss and disrupt of
maternal behaviors.
 In the experiments for cornparison between bisphenolA and 17P-estradiol, mice were
orally administered either olive oil (control, O.1 mLlkg), bisphenol-A (3 ptg/kg/day or
200 mg/kglday) dissolved in olive oil (Wako Pure Chemicals) or 17P-estradiol (3
ptg/kg/day), through stomach sonde. Female mice (10 weeks old) were orally treated
with these chemicals three times a day (8:OO, 14:OO, 20:OO) from mating to weaning.
Place conditioning
 Place conditioning was performed according to the method described in Chapter 2.
Measurement of locomotor activity
 The locomotor activity of mice was measured following the method described in
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Chapter 2.
[35S]GTPyS binding assay
 [35SIGTPyS binding assay was conducted as described in Chapter 2.
Statistical analysis
 Data represent the mean counts with SEM. Statistical anaiyses were performed using
one-way ANOVA with Bonferroni/Dunnett's test.
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Result
Enhancement of morphine-induced rewarding effect in mice prenatally and
neonatally exposed to low-dose bisphenol-A
 At the dose of 1 mg/kg (s.c.), morphine produced neither place preference nor place
aversion in control mice (Fig. 4-IA). However, treatment with 1 mg/kg (s.c.) of
morphine produced a significant place preference in mice chronically treated with low-
dose bisphenol-A from mating to weaning (*p Åq O.05 vs. control group, Fig. 4- IA).
Enhancement of morphine-induced hyperlocomotion in mice prenatally and
neonatally exposed to low-dose bisphenol-A
 Treatment with 10 mglkg (s.c.) of morphine produced a locomotor-enhancing effect in
all groups (Fig. 4-IB). In mice chronically treated with low-dose bisphenol-A, the
hyperlocomotion induced by morphine was dramatically potentiated as compared to that
in control (Fig. 4-IB).
Dopamine-induced G-protein activation in the limbic forebrain of mice prenatally
and neonatally exposed to low-dose bisphenol-A
 The enhancement of the stimulation of [35S]GTPyS binding induced by dopamine (10
ptM) was noted in the limbic forebrain of mice chronically treated with low-dose
bisphenol-A ("*p Åq O.Ol vs. control group. Fig. 4-IC).
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Enhancement of morphine-induced rewarding effect in mice prenatally and
neonatally exposed to low and high doses bisphenol-A but not 17P-estradiol
 At the dose of 1 mglkg (s.c.), morphine produced neither place preference nor place
aversion in control mice (Fig. 4-2). On the other hand, treatment with 1 mglkg of
morphine produced a significant place preference in mice prenatally and neonatally
exposed to low and high doses bisphenol-A (*p Åq O.05 vs. control group, Fig. 4-2). In
contrast, treatment with morphine at 1 mglkg failed to produce a significant place
preference in offspring of mothers that had been chronically treated with 176-estradiol
(Fig. 4-2).
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Discussion
 As described in previous chapters, the chronic treatment of high-dose bisphenol-A
induced the supersensitivity of pharmacological action of morphine associated with the
disruption of dopaminergic neuron development. These phenomena were observed in
mice chronically treated with bisphenol-A-admixed powder food containing 2 x 103 ug
bisphenol-Alg of food during the developmental period. Under these conditions, the
blood level of bisphenol-A in their pups was approximately 10 ngfmL, which is
considered to be more than 30 times higher than the level for healthy human exposure').
On the other hand, vom Saal et al. estimated that humans are exposed to bisphenol-A at
a dose of 2 to 20 ptglkg!day79). Based on these reports, I here ascertained the effects of
low-dose exposure to bisphenol-A. Adult female mice were chronically treated with
bisphenol-A-admixed powder food containing zero (control) or 3 x 10-2 ptg bisphenol-
Alg of food from mating to weaning. Here I found that prenatal and neonatal exposures
to low-dose bisphenol-A also enhanced the pharmacological actions of morphine
associated with functional potentiation of dopamine receptor in the limbic forebrain.
 Bisphenol-A and alkylphenols have been reported to have estrogenic activity80). Recent
molecular studies have suggested the transcriptional activation of the human dopamine
Di receptor gene by estrogen8'). Therefore the supersensitivity of morphine-induced
pharmacological actions caused by prenatal and neonatal exposures to low-dose
bisphenol-A may be mediated through estrogen receptors. I next investigated whether
prenatal and neonatal exposures to 176-estradiol induce the potentiation of morphine-
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induced rewarding effect. I found that prenatal and neonatal exposures to low and high
doses bisphenol-A (3 pg or 200 mg!kglday administered by oral administration) clearly
enhanced the rewarding effects of morphiRe in mice. In contrast, treatment with 176-
estradiol (3 pglkglday, administered orally) had no such effects. These findings indicate
that the potentiation of morphine-induced rewarding effects induced by prenatal and
neonatal exposure to bisphenol-A can be mediated by the nonestrogenic actions of
bisphenol-A. It has been reported that equal doses bisphenol-A and 17P-estradiol could
activate CREB via nonclassical estrogen receptors, resulting in the transcriptional
activation of CREB-responsive genes`8). On the other hand, obyious differences between
bisphenolA and 17P-estradiol have also been reported. For example, 17fi-estradiol at
10 nM reduced the duration of Ca2' oscillations in mouse oocytes, whereas
concentrations of bisphenol-A as high as 100 ptM were necessary for similar inhibition`9).
It has been reported that 17S-estradiol inhibits the astrocytic uptake of glutamate, which
is the most important excitatory neurotransmitter in the CNS, whereas bisphenol-A has
no such effect50). Taken together, these observations suggest that bisphenol-A and 17P-
estradiol may be coupled to different signaling cascades in the CNS. As mentioned in
chapter 1, in vitro experiments indicate that the enhancement of Ca2' responses to
dopamine indueed by bisphenol-A could lead to an increase in the excitability of central
dopaminergic neurotransmissions in both neuroRs and astrocytes mediated by
nonhormonergic actions of bisphenol-A. As mentioned aboye, bisphenol-A has only
weak estrogenic activities. Therefore it is difficult to explain whether the enhancement
of dopaminergic transmission in mice prenatally and neonatally exposed to low-dose
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bisphenol-A could be induced by estrogenic activities of bisphenol-A. Taken together,
these results indicate that the eBhancement of dopaminergic transmission in neurons and
astrocytes induced by nonhormonergic actions of bisphenol-A may, at Ieast in part, lead
to the aggravation of the development of psychological dependence on morphine.
 In regard to endocrine disruptor problems, the low-dose actions are serious problems.
Besides the description in the present study, it was recently reported that there were
effects caused by exposure to low-dose bisphenol-A on the rate of growth and sexual
maturation, hormone levels in blood, reproductive organ function, fertility, immune
function, enzyme actiyity, and brain structure, brain chemistry, and behavior82).
Therefore the present findings warn that prenatal and postnatal exposures to not only
high-dose, but also low-dose bisphenol-A may dramatically change the neuronal
transmission, including dopaminergic transmission in the adult brain. This phenomenon
could explain the aggravation of the development of dependence on drugs of abuse.
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                           Chapter 5
Memory impairment associated with a dysfunction of the hippocampal cholinergic
system induced by prenatal and neonata1 exposures to bisphenol-A
68
                               Introduction
 As mentioned in previous chapters, chronic exposure to bisphenol-A during a
development period alters dopaminergic neurotransmission in the central nervous
system (CNS), which results in the enhancement of psychological dependence on drugs
of abuse.
 The fetus uses natural hormonal messages that originate in its own hormone system
and that of its mother for developmental guidance. Although bisphenol-A has weak
estrogenic activity, prenatal and neonatal exposures to 17P-estradiol failed to induce the
supersensitivity of morphine described in chapter 4. Furthermore, although it is well
known that bisphenol-A disrupts thyroid hormone, prenatal qnd neonatal exposures to
propylthiouracil, a thyroid hormone inhibitor, reduced the activation of dopaminergic
neurons. These findings indicate that the disruption of dopaminergic neuron
development induced by prenatal and neonatal exposures to bisphenol-A can be
mediated by nonhormonergic actions of bisphenol-A. Furthermore, my preliminary
biochemical studies showed that bisphenol-A has an affinity for nonspecific binding
sites. Thus, since its action site remained unclear, it is most likely that prenatal and
neonatal exposures to bisphenol-A induce other behavioral abnormalities associated
with the alternation not only of the dopaminergic system, but also of other
neurotransmissions. The present study was then undertaken to investigate whether
prenatal and neonatal exposures to bisphenol-A could alter other behavioral
abnormalities such as anxiogenic behavior, motor learning behavior, and memory.
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 On the endocrine disruptor problems, the Iow-dose actions of the endocrine-disrupting
chemicals are serious problems, as described in chapter 4. However, little is known
about action on the CNS induced by low-dose bisphenol-A. I also investigated whether
prenatal and neonatal exposures to low-dose bisphenol-A in mice could induce
behavioral abnormalities.
70
Materials and Methods
Animals
 All experiments were performed using 7-11 weeks old male C57BL16J mice (Japan
SLC, Inc., Shizuoka, Japan) that had been prenatally and neonatally exposed to
bisphenol-A (Wako Pure Chemical Industries Ltd., Osaka, Japan). Adult female mice
(10 weeks old) were chronically treated with bisphenol-A-admixed powder food
containing O (control), 3 x 10'2, 2 x 103 ptg bisphenol-A/g of food from mating to
weaning. Their pups were prenatally and neonatally exposed to the respective
concentration of bisphenol-A from their mothers. During the treatment with bisphenol--
A, animals did not show body weight loss.
Light-dark test
 To investigate changes in anxiogenic-like effects, mice were tested using the
lightKlark paradigm 83'8`). I used a box consisting of a small (18 x 13 x 18 cm) dimly lit
compartment with black walls and a black floor, connected by a small opening (5 x 5
cm) to a large (18 x 18 x 18 cm) intensely lit (500 lux) compartment with a white walls
and a white floor. Each animal was placed in the dark compartment at the beginning of
the obseryation session. Compartment entry aRd exit were defined as all four paws into
and out, respectively. The time spent in the lit compartment was recorded for 10 min.
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Elevated plus-maze
 As another mesprement of anxiety, the mice prenatally and neonatally exosured to
bisphenol-A were evaluated by the elevated plus-maze paradigm. The elevated plus-
maze consists of two opposing open arms (30 x 6 x O.3 cm) and two opposing enclosed
arms (30 x 6 x 15 cm) that are connected by a central platform (9 x 9 cm, 100 lux), thus
forming the shape of a plus sign. Each animal was tested using the elevated plus-maze
in each experiment. The time spent in open or enclosed arms and entry into open or
enclosed arms were recorded for 5 min. The results were calculated as mean ratios of
the time spent in the open arms to the total time spent in both the open and enclosed
arms.
Rota-rod performance procedure
 To investigate possible changes in motor leaming impairment with prenatal and
neonatal exposure to bisphenol-A, mice were tested using the rota-rod performance
procedure (rota-rod test). The apparatus consisted of a base platform and a rotating rod
with a diameter of 3 cm and a non-slippery surface. The rod with 30 cm length was
placed at a height of 15 cm from the base. The rod was divided into 5 equal sections by
6 disks. Thus, mice were tested simultaneously on the apparatus, with rod--rotating
speed of 10 rpm. A rota-rod test during which each animal was placed on a rotating rod
and had to move forward; if the mouse stayed on the rotating rod for 5 min, the rota-rod
test was stopped; each animal was tested for 5 min. The mouse was replaced on the
rotating rod immediately after the mouse fell from the rotating rod. I measured the time
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until falling first time and the numbers of falling during 5 min as the indicators of motor
impairment twice a day. The score was the mean of latencies or numbers of falling in
two trials.
Step-through passive avoidance test
 The influence of prenatal and neonatal exposure to bisphenol-A on memory processes
in mice was evaluated by the step-through passiye avoidance test. The experimental
apparatus for the step-through passive avoidance test is a shuttle--box that is divided into
an illuminated small compartment (12 x 5 x 14 cm) and a darkllarge compartment (25 x
25 x 20 cm) by a wall with a guillotine door. At the first day (conditioning day), each
animal was placed in the illuminated compartment. After 90 sec, the door was opened
and the mouse moved into the dark compartment freely. The door was closed as soon as
the mouse stepped into the dark compartment and an inescapable foot shock (O.5 mA,
O.5 s) was delivered through the grid floor. After 48 hr from conditioning day, retention
test was started. The retention test was performed in the similar manner without the
electric shock and the step-through latency to the dark compartment was recorded.
The maximal cut-off time for step-through latency was 30 min.
Immunohistochemistry
 Immunohistochemistry was performed according to the method described in Chapter 2.
The brains were then quickly removed after perfusion, and thick coronal sections of the
midbrain including the hippocampus were initially dissected using Brain Blocker. The
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brain sections were blocked in 39o normal horse serum with O.29o Triton X-100 in
O.OIM PBS for 1 hr at room temperature. The primary antibody of choline
acetyltransferase (ChAT, 1: 100 Chemicon International Inc., CA, USA) was diluted in
O.Ol M PBS containing 39o NHS with O.29o Triton X-100 and incubated for 2 days at
40C. The samples were then rinsed and incubated with the appropriate secondary
antibody conjugated with Alexa 488 for 2 hr at room temperature. Fluorescence
immunolabeling was observed with a iight microscope and photographed with a digital
camera as described in Chapter 2. Digitized images of the dentate gyrus were captured
at a resolution of 140 - 200 pixels with a digital camera (Polaroid PDMCII/OL;
Olympus). The density of ChAT labeling was measured with a computer-assisted
imaging analysis system (Image J program, developed at the National Institutes of
Health available at http://rsb.info.nih.gov/ij). The upper and lower threshold density
ranges were adjusted to encompass and match the immunoreactivity; this provided an
image with immunoreactive material appearing in black pixels and non-immunoreactive
material in white pixels. A standardized rectangle was positioned over the hippocampus
of control mice. The area and density of pixels within the threshold value representing
immunoreactivity were calculated and the integrated density was the product of the area
and density The same box was then `dragged' to the corresponding position on the
hippocampus of bisphenol-A treated mice, and the integrated density of pixels within
the same threshold was again calculated.
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Statistical analysis
 All of data represent the mean counts with SEM. Statistical analyses were performed
using one-way or two-way ANOVA with Bonferroni/Dunnett's test.
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Result
Lack of anxiogenic effect by prenatal and neonatal exposure to bisphenol-A
 In the present study, prenatal and neonatai exposure to bisphenol-A failed to induce
anxiogenic-like effect using the light-dark paradigm (Fig. 5-1-A). As another
measurement of anxiety, the mice prenatally and neonatally exposed to bisphenol-A
were evaluated by the elevated plus-maze paradigm. The percentage of time spent in the
open arms in the mice prenatally and neonatally exposed to bisphenol-A were shown in
Fig. 5-1-B. The prenatal and neonatal exposure to bisphenol-A failed to affect the
percentage of time spent in the open arms.
Lack of motor learning impairment by prenatal and neonatal exposure to
bisphenol-A
 To investigate possible changes in motor learning impairment with prenatal and
neonatal exposure to bisphenol-A, mice were tested using the rota-rod test. In the
present study, the mice prenatally and neonatally exposed to low or high doses
bisphenol-A progressively improved their skill in the rota-rod test as like control mice
(Fig. 5-1-C, D). The improvement of latency to fall and number of falling in the rota-rod
test were indistinguishable between control and bisphenol--A treated mice (Fig. 5-1-C,
D). These results suggest that prenatal and neonatal exposure to bisphenol-A has no
direct effect on motor skill learning.
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Memory impairment induced by prenatal and neonata1 exposure to bisphenol-A
 The influence of prenatal and neonatal exposure to bisphnol-A on memory processes in
mice was evaluated by the step--through passive avoidance test. In the conditioning trial,
the step-through latency of the mice prenatally and neonatally exposed to low and high
doses bisphenol-A was similar to that of control mice (Fig. 5-1-E). The mice prenatally
and neonatally exposed to bisphenol-A dramatically decrease latencies to step into the
dark compartment as compared with control mice, although all groups increased the
latency to step into the dark compartment compared with the latency shown at
conditioning (Low; Fag)=6.246, pÅqO.05 vs. control, High; F(uo)=9.167, pÅqO.05 vs.
control, Fig. 5-1-F).
Dramatical reduction in ChAT-1ike immunoreactivitiy in the hippocampus of mice
prenatally and neonatally exposed to low and high doses bisphenol-A
 Immunohistochemical study showed that prenatal and neonatal exposures to low- and
high-doses bisphenol-A dramatically decreased the level of choline acetyltransferase-
like immuRoreactivity (ChAT-IR) in the widespread regions of the hippocampus
compared to control (Fig. 5-2-Ai-iii). Especially, as shown in high magnification images,
cholinergic fiber was dramatically decreased in mice prenatally and neonatally exposed
to low- and high-doses bisphenol-A compared to control (Fig. 5-2-Bi-iii). Furthermore,
these phenomena were observed in several regions of the hippocampus such as CAI,
CA2 and CA3 (data not shown). Using semi-quantitative analysis, prenatal and neonatal
low- and high-doses bisphenol-A produced a significant decrease in the ievel of ChAT-
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IR in the hippocampus (Low:
High: 50.0 Å} 3.8 9o of control,
64.3 Å} 5.6 9o of control, **"p Åq O.OOI
*** p Åq O.OOI vs. control mice, 5-2-C).
ys. control mice;
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and recejNed u t'oot shock tts svon as thc.N s. tepped i-to lhe dark eonipartnient. 'rhe step-threugh latenc.N'
ol'
 lhe niicc prenuuillÅr' and neenttt"llÅr, exposed ce lo"'- tind hi.gh-doses ot' bisphenol-A "'us siniilur to thul
ot' eontrol n]ice, (};) Prenala] nncl neenttlal e.xposuret' te lo",- and hiyh-dose! bi.sphenol-,A induced a
signit'ie.'mt tneinory inipnirinent (Low: Ftt,,n=6.246, pÅqO.05 ys. centrol. High: F","n=9.]67, l)ÅqO,e5 Ns.
control}. E"cl] point repre:'ents the niean with SE)vl o{' 5-7 niiee/.yroup.
79
{yVl
(' .•X11)
f.-V1
(C}
    -,
 T. ..,
 E
  5 fu;.
  'J
 5 :,
 xv
 v  ][.)
    11
-
i: : L; )i:
 t/ ;i::ÅÄ:/:(
tBi)
(' Bii)
il Biii)
         '
      w.
Contrul L.o" High
Fig. 5-2 Dramatical reduction in ChAT-like immunoreactiviti.y 'tn the hippocampus oti
mice prenatatly and neonatally exposed to low- and high-doses bispheno[-A (,ALi-iii)
Prenutal and neonatal exposures to low (Aii)- and hi.gh-doses (Aiii) bisphenol-A dramatically
decreaseL'i the levot ot' Ch.ALT-IR in the hippocampus compared t() centrol (.Ai}. (Bi-iii) Hi.gh
magnification ima(.,.es showed ChAT-IR in the DG. ChAT-IR was dramaticaliy decreased in the
DG by prenatal and neonatal expesures. to low ÅqBii)- and high-doscs (Biii) as compared to
control (Bi). (C) Semi-quantitatiN'e analysis of Ch.ALT-IR was performed using Ima.ge J (Low:
64,3 -.+- 5.6 C/( of centro.1. "*"p Åq O.OOI vt . contt'ol mice:High: 50.0 Å}3.8 `lc ofcontrol."'"p Åq
O.OO1 vs. c,entrol mice). Each eolumn represents the nicun Å} SF.M of' three independent sttmples'.
DG: dentttte gyrus. Scale bars: 50 gM.
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Discussion
 In the present study, prenatal and neonatal exposures to bisphenol-A, using the light-
dark paradigm and the elevated plus-maze paradigm, failed to induce anxiogenic-like
effects. These results suggest that these exposures induced no anxiogenic-Iike behaviors.
Furthermore, to investigate possible changes in motor learning impairment by prenatal
and neonatal exposures to bisphenol-A, the mice were tested by means of the rota-rod
test. I found that the mice prenatally and neonataliy exposed to low-dose or high-dose
bisphenol-A progressively improved their skills in the rota-rod test as the control mice
did. Furthermore, the improvement of latency to fall and the number falling in the rota-
rod test were indistinguishable between the control and bisphenol-A treated mice. These
results suggest that prenatal and neonatal exposures to bisphenol-A has no direct effect
on motor skill learning.
 On the other hand, the influence of prenatal and neonatal exposures to bisphenol-A on
memory processes in mice was evaluated by the step-through passive avoidance tesL In
the conditioning trial, the step-through latency of mice prenatally and neonatally
exposed to low and high doses bisphenol-A was similar to that of control mice. The
mice prenatally and neonatally exposed to bisphenol-A dramatically decrease latencies
to step into the dark compartment in comparison with the control mice, though all
groups increased the Iatency to step into the dark compartment compared with the
latency shown at conditioning. These results strongly suggest that chronic treatment
with low and high doses bisphenol-A induced the memory impairment. The contextual
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fear conditioning is hippocampal-dependent memory. Therefore I next investigated the
morphological and/or functional changes in the hippocampus of mice prenatally and
neonatally exposed to low and high doses bisphenol-A.
 Immunohistochemical study showed that prenatal and neonatal exposures to low and
high doses bisphenol-A dramatically decreased the level of ChAT-IR in the widespread
regions of the hippocampus compared to control. It is widely accepted that the
cholinergic function in the hippocampus is important for the learning and memory
processes858'). Among the cholinergic parameters described for the brains of
Alzheimer's disease patients, the decrease in ChAT activity is the most prominent and
provides an excellent biochemical correlation to the severity of dementia. These reports
strongly support my findings that the memory impairment corresponded well to the
dysfunction of cholinergic neurons in the hippocampus of mice prefiatally and
neonatally exposed to bisphenol-A.
 As described in previous chapters, it is widely accepted that one of the most common
endocrine disruptors, bisphenol-A, has weak estrogenic activity. Moreover, an
endogenous estrogen, 17P-estradiol, plays the critical role in the neurotransmission of
the hippocampus associated with spinogenesis or neuroprotectiongg'89). Furthermore,
many cholinergic neurons also express the growth-associated protein GAP-43, which
may be taken as a marker of neurite outgrowth90). Estrogens, among other factors, up-
regulate the expression of GAP-43 in the developing and adult brain9'). On the other
hand, bisphenol-A also disrupts the thyroid hormone. Thyroid hormone deficiency
during brain development disrupts on the activities of enzymes of central acetylcholine
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metabolism, the activities of ChAT and acetylcholinesterase in the hippocampus92).
Actually, exposure to polychlorinated biphenyls, well known as one of the most
common thyroid hormone disruptors, suppressed ChAT activity and spatial learning and
memory deficits93'9`). According to these reports, I hypothesized that the memory
impairment induced by prenatal and neonatal exposures to bisphenol-A could be
mediated by the disruption of endogenous hormones in the developing brain.
 In the previous chapters, I described that prenatal and neonatal exposures to bisphenol-
A potentiated the dopaminergic neurotransmission. As mentioned above, this
phenomenon was induced by the nonhormonergic effect of bisphenol-A. In the present
study, I found that memory impairment associated with a drastic reduction of ChAT-IR
in the hippocampus was induced by prenatal and neonatal exposures not only to high-
dose bisphenol-A, but also to low-dose. Although it is very difficult to explain where the
primary action site of bisphenol-A is, I must therefore consider its mechanism through
nonhormonergic effect.
 Knaak and Sullivan (1966) first reported the metabolic fate of bisphenol-A in rats,
showing that the major metabolite in urine was the glucuronide of bisphenol-A; sizable
amounts of free bisphenol-A and hydroxylated bisphenol-A were found in feces7D.
Many reports have shown that bisphenol-A is metabolized and excreted rapidly9'on).
Taken together, it is almost impossible that the bisphenol-A that remained in the adult
brain of mice directly affects the CNS. Therefore prenatal and neonatal exposures to
bisphenol-A disrupts the neuron development, resulting in behavioral abnormalities in
adult animals.
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 In conclusion, the present findings provide direct eyidence that prenatal and neonatal
exposures not only to high-dose, but also to low-dose bisphenol-A, dramatically
decrease the cholinergic transmission in the adult brain, and this results in learning and
memory deficits.
84
                         General Conclusion
These findings lead to the following conclusions.
In Chapter 1:
 In the present study, I demonstrated for the first time that in vitro treatment with low--
dose bisphenol-A could lead to astrocytic activation according without the steroid-
hormonergic effects of bisphenol-A.
In Chapter 2:
 The present findings provide that the organogenesis and lactation are the most
important periods to cause a disruption of dopaminergic neuron development by
bisphenol-A exposure in the mouse.
In Chapter 3:
 The present data proyide direct evidence that prenatal and neonatal exposures to
bisphenol-A disrupts the dopaminergic neurotransmission in the process of
dopaminergic neuron development associated with changes in dopaminergic neuron
developmental factors.
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In Chapter 4:
 Based on the present study, I can warn that prenatal and postnatal exposures not only
to high-dose, but also to low-dose bisphenol-A, may dramatically change the neuronal
transmission, including dopaminergic transmission, in the adult brain.
In Chapter 5:
 The present findings provide direct evidence that prenatal and neonatal exposures to
low and high doses bisphenol-A-induced memory impairment associated with a
dysfunction of the hippocampal cholinergic system.
Final conclusion:
 For several years, concern has been growing oyer changes in the health and fecundity
of humans and wildlife that may be associated with the disruption of hormonal systems
by environmental chemicals. The issue of environmental endocrine disruptors has
become a focus of considerable media attention worldwide and is now on the agenda of
many expert groups, panels, and steering committees of governmental organizations,
industry, and academia in Europe, the United States, and Japan. Recently, several
reports have suggested that endocrine disruptors also affect the central neryous systems.
 In the present study, I investigated the relationship between prenatal and neonatal
exposures to bisphenol-A and the dopaminergic neuron development. I found that
prenatal and neonatal exposures to bisphenol-A could disrupt dopaminergic neuron
development associated with astrocytic activation, and it may, at least in part, contribute
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to the potentiation of the development of psychological dependence on drugs of abuse.
On the endocrine disruptor problems, the low-dose actions of the endocrine disruptor
are serious problems. I found that changes in the dopaminergic neurotransmissions were
induced by prenatal and neonatal exposures to bisphenol-A at a dosage lower than the
" Lowest Observed Adverse Effect Level."
 On the other hand,I found that prenatal and neonatal exposures to low and high doses
bisphenol-A also induced memory impairment associated with a dysfunction of the
hippocampal cholinergic system.
 Taken together, prenatal and neonatal exposures to bisphenol-A could disrupt the
various neuron developments, resulting in long-lasting abnormalities in yarious
neurotransmlsslons.
 It is ironic that the chemicals made for a convenient Iife could be harmful to our health.
I hope this research will be a warning about the problems of endocrine disruptors.
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